Resmed (RMD) Research & Development (2009 - 2026)

Resmed's Research & Development history runs 18 years deep, the most recent figure standing at $94.3 million for Q1 2026.

• Quarterly Research & Development rose 12.3% year-over-year to $94.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $359.0 million (up 10.22% YoY) and the FY2025 annual result came in at $331.3 million, up 7.73% from the prior year.
• Research & Development was $94.3 million for Q1 2026 at Resmed, up from $91.0 million in the prior quarter.
• Across five years, Research & Development topped out at $94.3 million in Q1 2026 and bottomed at $63.2 million in Q3 2022.
• A 5-year average of $78.2 million and a median of $78.1 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development advanced 21.5% — and 2024, when it grew 0.83%.
• Resmed's Research & Development stood at $69.9 million in 2022, then climbed by 5.73% to $73.9 million in 2023, then increased by 10.14% to $81.4 million in 2024, then increased by 11.79% to $91.0 million in 2025, then gained by 3.63% to $94.3 million in 2026.
• Business Quant data shows RMD's Research & Development at $94.3 million in Q1 2026, $91.0 million in Q4 2025, and $87.3 million in Q3 2025.